EBS News and Press, Emergent Biosolutions Inc. From 04/19/21

Emergent BioSolutions (NYSE: EBS) has been asked by the Food and Drug Administration to stop production for Covid-19 vaccines. According to the company, the halt comes amid a botched batch of Johnson & Johnson shots within its Baltimore plant. Shares fell 9% following the ne...

Shares of Emergent BioSolutions (NYSE: EBS) were tumbling 9.9% lower as of noon EDT on Monday. The big drop came after the company revealed in a filing to the U.S. Securities and Exchange Commission (SEC) that it has agreed not to make any new material at its Bayview facility in Bal...

GAITHERSBURG, Md., April 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial results for the first quarter of 2021, recent business developments, revenue guidance for the...

Shares of Emergent BioSolutions (NYSE: EBS) were trading 3.8% lower as of 3:01 p.m. EDT on Tuesday. The decline came after the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) called for a pause in the administration of Johnson &...

Data from the Centers for Disease Control and Prevention indicates that beginning April 12, the federal government will distribute ~86% fewer doses of Johnson and Johnson's (JNJ) COVID-19 vaccine compared to the prior week.Just 700K J&J vaccine doses will go out next week compared to 4,94...

Entwistle & Cappucci LLP (“Entwistle & Cappucci”) is investigating potential federal securities law violations on behalf of clients that invested in Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) based on: (i) the C...

Today pre-market analyst action includes downgrades on Fibrogen and ACADIA due to recent FDA decisions on companies’ new drug applications.Fibrogen slips as analysts weigh in on safety updateFibrogen (FGEN) shares plunged in the post-market yesterday in reaction to clarification m...

A scathing article in The New York Times on a troubled Emergent BioSciences (EBS) plant where two COVID-19 vaccines were produced found that the site was ill-equipped to handle such an undertaking and had persistent cleanliness issues.The piece, based on interviews with former federal of...

Johnson & Johnson (NYSE: JNJ) is the very definition of a value stock : five consecutive years of annual revenue growth, an above-average dividend that has been raised for 58 consecutive years in a row, and a diversified product portfolio capable of weathering various lawsui...

The U.S. government has given Johnson & Johnson (NYSE: JNJ) control of a Baltimore production facility operated by Emergent BioSolutions (NYSE: EBS) . The move is the latest development in a controversy over Emergent's production of Johnson & Johnson's coronaviru...